Skip to main
SGHT

Sight Sciences (SGHT) Stock Forecast & Price Target

Sight Sciences (SGHT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Sight Sciences Inc. exhibits a positive outlook due to the potential for stronger revenue growth, driven by faster-than-expected market share gains in the Minimally Invasive Glaucoma Surgery (MIGS) sector and quicker adoption of the TearCare System. The company's investment thesis highlights the capability of its Surgical Glaucoma business to sustain growth in alignment with the overall MIGS market. Additionally, the upward revision of earnings per share (EPS) forecasts for 2025 and 2026, moving to ($1.04) and ($0.88) respectively, points towards improving financial performance as the company progresses towards profitability.

Bears say

Sight Sciences Inc. has reiterated its 2025 revenue guidance of $72-76 million while also forecasting a mid-single-digit year-over-year decline in Surgical Glaucoma revenue for the third quarter of 2025. The company faces significant risks, including rising competition in the minimally invasive glaucoma surgery (MIGS) sector, delays in obtaining insurance coverage for its TearCare product, and ongoing issues with cash burn. Furthermore, although management has adjusted its 2025 operating expense guidance downward to $95-99 million, the reduced expenses are unlikely to offset the overall revenue challenges and competitive pressures the company is encountering.

Sight Sciences (SGHT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sight Sciences (SGHT) Forecast

Analysts have given Sight Sciences (SGHT) a Buy based on their latest research and market trends.

According to 6 analysts, Sight Sciences (SGHT) has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.02, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.02, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sight Sciences (SGHT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.